Literature DB >> 8051702

Crystallization of inhibitor complexes of an N-terminal 24 kDa fragment of the DNA gyrase B protein.

R J Lewis1, O M Singh, C V Smith, A Maxwell, T Skarzynski, A J Wonacott, D B Wigley.   

Abstract

A 24 kDa N-terminal fragment of the Escherichia coli DNA gyrase B protein has been crystallized in the presence of novobiocin. One crystal form has been obtained that is orthorhombic, P2(1)2(1)2(1), with unit cell dimensions a = 40.3 A, b = 47.7 A, c = 111.9 A. The asymmetric unit of this crystal form contains one molecule (Vm = 2.24 A3/Da). Complete native data have been collected to 2.5 A resolution. This same protein fragment has also been crystallized in the presence of GR122222X, an inhibitor that is structurally related to cyclothialidine. These crystals also exhibit P2(1)2(1)2(1) symmetry but have unit cell dimensions of a = 68.8 A, b = 68.6 A, c = 48.6 A. The Vm value of this crystal form is 2.39 A3/Da, assuming one molecule in the asymmetric unit, and native data have been collected to 2.0 A resolution. Molecular replacement studies of both complexes are underway.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8051702     DOI: 10.1006/jmbi.1994.1480

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  10 in total

1.  Biophysical Studies of Bacterial Topoisomerases Substantiate Their Binding Modes to an Inhibitor.

Authors:  CongBao Kang; Yan Li; Joseph Cherian; Boping Liu; Hui Qi Ng; Michelle Yueqi Lee; Nur Huda Binte Ahmad; Zhi Ying Poh; Yun Xuan Wong; Qiwei Huang; Ying Lei Wong; Alvin W Hung; Jeffrey Hill; Thomas H Keller
Journal:  Biophys J       Date:  2015-11-03       Impact factor: 4.033

2.  Mode of action of GR122222X, a novel inhibitor of bacterial DNA gyrase.

Authors:  M Oram; B Dosanjh; N A Gormley; C V Smith; L M Fisher; A Maxwell; K Duncan
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

3.  GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin.

Authors:  M Stieger; P Angehrn; B Wohlgensinger; H Gmünder
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 4.  Mode of action of fluoroquinolones.

Authors:  D C Hooper
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 5.  The challenge of converting Gram-positive-only compounds into broad-spectrum antibiotics.

Authors:  Michelle F Richter; Paul J Hergenrother
Journal:  Ann N Y Acad Sci       Date:  2018-02-15       Impact factor: 5.691

6.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187.

Authors:  Scott Classen; Stephane Olland; James M Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

8.  The nature of inhibition of DNA gyrase by the coumarins and the cyclothialidines revealed by X-ray crystallography.

Authors:  R J Lewis; O M Singh; C V Smith; T Skarzynski; A Maxwell; A J Wonacott; D B Wigley
Journal:  EMBO J       Date:  1996-03-15       Impact factor: 11.598

9.  Ultraviolet resonance Raman study of drug binding in dihydrofolate reductase, gyrase, and catechol O-methyltransferase.

Authors:  V W Couling; P Fischer; D Klenerman; W Huber
Journal:  Biophys J       Date:  1998-08       Impact factor: 4.033

10.  The key DNA-binding residues in the C-terminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA).

Authors:  You-Yi Huang; Jiao-Yu Deng; Jing Gu; Zhi-Ping Zhang; Anthony Maxwell; Li-Jun Bi; Yuan-Yuan Chen; Ya-Feng Zhou; Zi-Niu Yu; Xian-En Zhang
Journal:  Nucleic Acids Res       Date:  2006-10-11       Impact factor: 16.971

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.